Navigation Links
GlaxoSmithKline Responds to JAMA Articles
Date:9/11/2007

/p>

two most prescribed oral anti-diabetic medicines -- metformin and

sulfonylurea -- apart from the well characterized fluid-related events

common to both Avandia and Actos.

2. In three epidemiological studies of databases with more than one

million diabetic patients, the risk of heart attack was similar for

Avandia compared to other anti-diabetic agents. A database study

comparing Avandia to Actos showed no difference between the two.

3. Two large epidemiology studies presented to the FDA Advisory Committee

and conducted independently of GSK by WellPoint and by the Department

of Defense/Tricare also showed no increased rates of heart attack

between Avandia and Actos.

Importantly, only Avandia has been shown to control blood sugar for up to five years and to be 32 percent more effective than metformin and 63 percent more effective than sulfonylurea in maintaining blood sugar control over the long-term. We know from clinical studies that effective treatment of diabetes requires intensive, long-term, day-to-day control of blood sugar levels to reduce the risk of serious complications (e.g., blindness, kidney failure, limb amputation, nerve injury) and ultimately save lives. Avandia is the most widely studied oral medication for Type 2 Diabetes, and is an important option for physicians who often need to prescribe several different diabetes medicines in combination to help their patients maintain blood sugar control.

The FDA is engaged in a full, objective analysis of the science, and will make its independent recommendations on the appropriate use of oral anti- diabetic medicines. GSK continues to support Avandia as safe and effective when used appropriately.

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and liv
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. GlaxoSmithKline - Changes Lamictal(R) Label Appearance and Packaging
2. GlaxoSmithKline To Cultivate Non-Smoking Environment
3. GlaxoSmithKline to Supply United States with 8 Million flu vaccine, Fluarix
4. FDA Mislead On Asthma Drug By GlaxoSmithKline
5. GlaxoSmithKline Defends Its Products
6. GlaxoSmithKline launches diabetes and cancer drugs
7. Generic Products Compete With GlaxoSmithKline
8. GlaxoSmithKline Agrees To Settle Paxil Claims For $14 million
9. GlaxoSmithKlines Zofran Helps In Treatment Of Dehydration In Children
10. Ranbaxy Acquires Glaxosmithklines Generic Unit in Spain
11. GlaxoSmithKline’s Epilepsy Drug given the Green Signal by FD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... The Muscular Dystrophy Association (MDA) and Jiffy Lube today announced ... campaign that will raise funds to help save and improve ... disease. , As part of the campaign, Jiffy ... through Sept. 1, 2014 to make a donation to MDA, ... fight for muscle health. Since 2012, Jiffy Lube has raised ...
(Date:7/22/2014)... 2014 The Restful Jaw Company announces ... Restful Jaw ®. The FDA-registered external device is clinically ... jaw pain, fatigue and soreness during dental procedures. As ... when patients do not need to take breaks or ... Jaw is a vital solution in helping more than ...
(Date:7/22/2014)... HealthDay Reporter MONDAY, July ... treat moderate-to-severe allergic asthma appears to offer relief to people ... new research suggests. The prescription drug -- omalizumab (Xolair) ... and Drug Administration approval earlier this year for that use. ... at a high dose for a six-month period it seems ...
(Date:7/22/2014)... 21, 2014) Investigators at the Cedars-Sinai Samuel ... multistep investigational treatment for one of the most ... advanced pancreatic cancer. , Locally advanced pancreatic ... solid tumor, with a cumulative five-year survival rate ... disease. Surgery is rarely an option for patients ...
(Date:7/22/2014)... 80 percent of all drug candidates in the ... therefore rejected early in the drug discovery process. ... material Upsalite, has great potential for development of ... findings could allow the pharma companies to open ... discarded due to solubility problems and try them ...
Breaking Medicine News(10 mins):Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 2Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 3Health News:Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw 2Health News:Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw 3Health News:Asthma Drug May Help Those With Chronic Hives 2Health News:Asthma Drug May Help Those With Chronic Hives 3Health News:Unique study focuses on combined treatment approach for locally advanced pancreatic cancer 2Health News:Unique study focuses on combined treatment approach for locally advanced pancreatic cancer 3Health News:Supermaterial gives rejected drugs a new chance 2
... that second twins born at term are at a higher ... than first twins. However, planned caesarean section may prevent such ... born in Scotland between 1995 and 1998. They found significantly ... second twins born at term. No deaths were recorded among ...
... is observed that women are more likely to experience non-specific ... shows that women are less likely to get prompt treatment ... for 'clotbusting' drugs must be given very rapidly if they ... suggest why there could be a delay in diagnosing stroke ...
... be a waste of time. It does little to reduce ... down by stretching was thought to reduce the risk// of ... out to be wrong, but the stretching habit stuck. It ... injury and improve performance”, comments physiotherapist Rob Herbert of the ...
... was observed that the valve helps patients with advanced esophagal ... is difficulty in swallowing. Unfortunately, the cancer is often well ... survival rates it is generally poor and quite often all ... comfortable as possible. ,Part of this involves inserting ...
... to a new research it is observed that a surgically ... The research focuses on draining cerebrospinal fluid. This type of ... procedure was no longer used// when there seemed to be ... Recent studies of this type of shunting on patients with ...
... a new drug may lower the need for blood ... drug, polymerized bovine hemoglobin (HBOC-201),// is delivered intravenously and ... structure of the HBOC-201 is smaller and more mobile ... effectively distribute oxygen throughout the body. ,The study, ...
Cached Medicine News:
(Date:7/22/2014)... 22, 2014 Elekta (NSE:EKTAb) and Royal ... Christie NHS Foundation Trust ( Manchester, UK ... whose mission is to develop the clinical value of ... system. Such a system would, in principle, improve the ... "The Christie was an essential participant ...
(Date:7/22/2014)... SAN DIEGO , July 22, 2014  Halozyme ... that it has resumed enrollment and dosing of patients ... PEGPH20 in patients with pancreatic cancer under the revised ... PEGPH20 is an investigational PEGylated form of Halozyme,s proprietary ... of tumors that accumulate hyaluronan. "Our ...
(Date:7/22/2014)...  Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. ... with the Icahn School of Medicine at ... ) to utilize its proprietary information and data package ... Niemann-Pick Type C Disease (NPC), a rare disease, mostly ... license also covers other diseases and disorders relying on ...
Breaking Medicine Technology:The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5
... N.J., Nov. 4 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ... months ended September 30, 2009, ending the quarter with $67.5 ... million from December 31, 2008. In October 2009, we ... offering costs from an underwritten public offering of 4,945,000 shares ...
... , PARIS, Nov. 4 Alcatel-Lucent (Euronext Paris and ... TeleHealth Manager, a secure and reliable remote patient monitoring ... Drug Administration (FDA) for marketing in the United States. ... supports remote patient monitoring with an easily deployable ...
Cached Medicine Technology:Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 2Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 3Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 4Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 5Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 7Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 8Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 9Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 10Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 11Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 12Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 13Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 14U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States 2U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States 3
... Intersurgical Incorporated manufactures high ... and moisture exchangers, ventilator ... hand-held nebulizers and an ... and connectors for anesthesia ...
... line has the right product for any ... from intubated patients to patients with tracheotomies. ... anesthesia and critical care applications., ,The ... for patients and staff members. This entire ...
... (HCH) capture the patient`s exhaled heat and ... gas. Small and compact, they are specially ... Depending on the tidal volume requirements, select ... ,The adult HCH is ideal for patient ...
... These hygroscopic condenser humidifiers (HCH) capture ... return them in the inspired gas. Small ... provide bacteriostatic and hygroscopic benefits. Depending on ... adult or small-volume model., ,The adult ...
Medicine Products: